Subscribe to Search results

Dr Duncan Thomas inspected Hyland Laboratories in California noting a hepatitis hazard associated with the products as a result of the nature of the donors and the large plasma pools.

Published on:

CSM(B) recommended the grant of a product licence for Hemofil.

Published on:

CSM(B) recommended the grant of a product licence for Kryobulin.

Published on:

A product licence was granted for Profilate made by Abbott Laboratories Ltd.

Published on:

CSM(B) recommended a product license be granted for Factor 8.

Published on:

DHSS Divisional Management Group meeting considered criticisms made by the documentary World in Action: Blood Money of Travenol's production of Factor 8.

Published on:

Dr David Owen considered Armour's application to supply Factorate to haemophilia centres.

Published on:

CSM recommended the grant of a product licence for Koate.

Published on:

An application was made by Immuno to vary the product licence in respect of Kryobulin to allow European plasma to be sold in red packs and US plasma to be sold in cheaper blue packs.

Published on:

An application by Immuno to vary the product licence in respect of Kryobulin to allow European plasma to be sold in red packs and US plasma to be sold in cheaper blue packs was approved.

Published on:

The Department of Health and Social Security informed Immuno approval had been granted to vary the product licence in respect of Kryobulin to allow European plasma in be sold in red packs and US plasma to be sold in cheaper blue packs.

Published on:

Licences for heat-treated Hemofil and Factorate were refused.

Published on:

FDA recommendation of steps including avoiding use of high risk plasma in US blood products was published.

Published on:

Paper from Dr Spence Galbraith recommended suspending importation of US blood products.

Published on:

The CSM endorsed the recommendation by the CSM(B) not to recommend action to stop continued importation of commercial concentrates.

Published on:

CSM(B) decided not to recommend action to stop continued importation of commercial concentrates.

Published on:

It was confirmed that import of factor products made from higher risk pre-March plasma would continue.

Published on:

CSM requested the Licensing Authority to invite early applications for licence variations to permit distribution and sale of heat-treated concentrates.

Published on:

Dr Yellowlees sent a 'Dear Doctor' letter to all Regional Medical Officers saying that collections from prisons could continue despite the higher risk of Hepatitis B if all donations were subjected to more sensitive Hepatitis B tests.

Published on:

Dr Walford wrote in a DHSS minute that NANBH could "be rapidly fatal" and "lead to progressive liver damage".

Published on: